By Mill Chart
Last update: Feb 14, 2024
Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is suited for growth investing. Investors should of course do their own research, but we spotted AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.
ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.
AMPH gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 204 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH is growing strongly while it also seems undervalued. This is an interesting combination This makes AMPH very considerable for value and growth investing!
Check the latest full fundamental report of AMPH for a complete fundamental analysis.
More growth stocks can be found in our Lois Navellier screen.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (4/19/2024, 7:00:00 PM)
After market: 40.1 +0.09 (+0.22%)40.01
+1.36 (+3.52%)
Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.